{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T03:03:28Z","timestamp":1788059008618,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Orthop Relat Res"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Although giant cell tumors (GCTs) are benign, their aggressiveness and tendency to recur locally challenge the orthopaedic surgeon\u2019s ability to perform joint-preserving intralesional surgery with an acceptably low risk of local recurrence. Denosumab has emerged as a possible medical treatment of GCT because it seems to halt the progression of GCT, alleviate pain, and increase perilesional bone formation, but its exact role has been questioned, and specifically its efficacy and associated complications are not well characterized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Questions\/purposes<\/jats:title>\n            <jats:p>(1) Does denosumab reduce the risk of recurrence after resection or intralesional surgery? (2) What are the complications associated with the use of denosumab?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifty-four patients with 30 primary and 25 recurrent tumors between November 2013 and July 2016 were treated with denosumab after a confirmed histopathologic diagnosis of GCT. Another 17 patients in the same period were treated without denosumab. During the study period, we encouraged the use of denosumab in all patients except those who refused, could not afford it, or where it was contraindicated (eg, in pregnancy). In all patients undergoing intralesional surgery, we arbitrarily planned six doses before surgery. Variations in total doses before surgery were dependent on patient-related factors; in some, we gave less doses because patients expressed the inability to afford any more doses, whereas in some patients, extra doses were added when the patient wished to delay surgery as well as the because of surgeon judgment wherein in some patients, we stopped before six doses when we thought adequate bone had formed for intralesional curettage. The mean number of doses was 6.8 per patient (median, 6; range, 3-17) preoperatively. The minimum followup was 12 months (median, 27 months; range, 12-42 months). Every patient showed improvement clinically in terms of pain and halting of tumor progression within three to four doses. This was seen radiologically as a sharply defined soft tissue mass as well as hazy ossification within the tumor. For a case-matched comparison study, we identified controls as 34 patients undergoing curettage from the retrospective analysis of 68 patients curetted without denosumab between February 2010 and July 2016 matched to 25 denosumab-treated patients in terms of site, size, Campanacci grade, and recurrent versus primary status, and with a minimum 2 years followup for the control group. Fisher\u2019s exact test was used for statistical study. Patients undergoing resection were planned for surgery after three doses of denosumab to allow the tumor to solidify and potentially decrease tumor spillage at the time of surgery. The resections could not be case-matched for comparison owing to the smaller numbers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed 14 recurrences out of the 37 curetted tumors (38%). In the case-matched analysis, 11 of 25 patients in the denosumab-treated curettage group had recurrences (44%) compared with seven of 34 (21%) in the nondenosumab-treated control group. The risk of denosumab-treated patients experiencing local recurrence as compared with the nondenosumab-treated patients was nonsignificant with a two-tailed p value of 0.085 (significance at p &lt; 0.05) as derived from Fisher\u2019s exact test (odds ratio, 3.03; 95% confidence interval, 0.96\u20139.54). There was no recurrence in the resection group. Because we do not have a control group for resection, we are unable to comment on the importance of this finding. One major complication that we observed was a recurrence with malignant transformation in a patient with a proximal humeral GCT. We did not observe any other complications related to the denosumab therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although we could not demonstrate a higher risk of local recurrence with preoperative denosumab for intralesional surgery in the dose and frequency we administered, we advise caution in its routine use for intralesional procedures because it may be important to curette up to margins on pretreatment imaging owing to the potential residual tumor within the denosumab-mediated thick bony shell, which may result in local recurrence. We believe that denosumab treatment before resection of a large tumor aids resection without tumor spillage, particularly where important structures like the neurovascular bundle are dissected away from the tumor margin, although we cannot confirm that it helps lower the incidence of recurrence. We are concerned regarding the malignancy-causing potential from our observation in one patient as well as reports of this by others and recommend judicious use of this drug in patients with GCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Level of Evidence<\/jats:title>\n            <jats:p>Level III, therapeutic study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11999.0000000000000243","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T15:21:55Z","timestamp":1530199315000},"page":"1773-1782","source":"Crossref","is-referenced-by-count":74,"title":["Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience"],"prefix":"10.1097","volume":"476","author":[{"given":"Manish G.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manit K.","family":"Gundavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,2,24]]},"reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"767198","DOI":"10.1155\/2015\/767198","article-title":"Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab","volume":"2015","author":"Broehm","year":"2015","journal-title":"Case Rep Med."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin Sarcoma Res."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijscr.2014.09.018","article-title":"The dilemma of denosumab: salvage of a femoral head giant cell tumour","volume":"5","author":"Gaston","year":"2014","journal-title":"Int J Surg Case Rep."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1746-1596-9-111","article-title":"Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab","volume":"9","author":"Hakozaki","year":"2014","journal-title":"Diagn Pathol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect Tissue Res."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12094-014-1268-5","article-title":"Giant cell tumour of bone: new treatments in development","volume":"17","author":"Lopez-Pousa","year":"2015","journal-title":"Clin Transl Oncol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.2106\/JBJS.M.01332","article-title":"A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab","volume":"96","author":"Mak","year":"2014","journal-title":"J Bone Joint Surg Am."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1874325001307010103","article-title":"A systematic review and meta-analysis of en-bloc vs intralesional resection for giant cell tumor of bone of the distal radius","volume":"7","author":"Pazionis","year":"2013","journal-title":"Open Orthop J."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2017.02.008","article-title":"Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls","volume":"63","author":"Roitman","year":"2017","journal-title":"Hum Pathol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"749","DOI":"10.21873\/anticanres.11373","article-title":"Pathogenesis of osteosclerotic change following treatment with an antibody against RANKL for giant cell tumour of the bone","volume":"37","author":"Rosario","year":"2017","journal-title":"Anticancer Res."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann Surg Oncol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab\u2013a case report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol."},{"key":"R17-20230814","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.RVW.16.00072","article-title":"The role of denosumab in the modern treatment of giant cell tumor of bone","author":"Thornley","year":"2017","journal-title":"JBJS Rev."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.01.006","article-title":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone","volume":"59","author":"Traub","year":"2016","journal-title":"Eur J Cancer."}],"container-title":["Clinical Orthopaedics &amp; Related Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003086-201809000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:49:53Z","timestamp":1691992193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003086-201809000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1007\/s11999.0000000000000243","relation":{},"ISSN":["0009-921X"],"issn-type":[{"value":"0009-921X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,24]]}}}